Page 2 - மதிப்பீடு ஆஃப் ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மதிப்பீடு ஆஃப் ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மதிப்பீடு ஆஃப் ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் Today - Breaking & Trending Today

Major Advance in the Treatment of Axial Spondyloarthritis Coming

Major Advance in the Treatment of Axial Spondyloarthritis Coming
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Northwestern University , United States , Saudi Arabia , University Of Pennsylvania , San Diego , Alexisr Ogdie , Ericm Ruderman , Arthur Kavanaugh , Jeffreyr Curtis , University Of California , Drug Administration , American College Of Rheumatology , Peuropean League Against Rheumatism , University Of Alabama At Birmingham , Assessment Of Spondyloarthritis International Society , European Alliance Of Associations , Winter Clinical , Are Coming , American College , Spondyloarthritis International Society , European Alliance , Bath Ankylosing Spondylitis Disease Activity , Biologics Arent Equal When It Comes , Anterior Uveitis Risk , Swedish Rheumatology Quality Register , Innovative Therapy ,

AbbVie's Rinvoq bags two new EU approvals

AbbVie s Rinvoq bags two new EU approvals
26th January 2021
The European Commission (EC) has approved AbbVie’s Rinvoq (upadacitinib) for the treatment of active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
The oral JAK inhibitor has been indicated for the treatment of active PsA in adult patients who have inadequately responded to or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Rinvoq has also been indicated for the treatment of active AS in adult patients who have responded inadequately to conventional therapy.
These new approvals for Rinvoq were supported by data from three clinical trials – SELECT-PsA 1, SELECT-PsA 2 and SELECT-AXIS 1. ....

Abbvie Rinvoq , Tom Hudson , European Commission , Assessment Of Spondyloarthritis International Society , Spondyloarthritis International Society , டோம் ஹட்சன் , ஐரோப்பிய தரகு , மதிப்பீடு ஆஃப் ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் , ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் ,

European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

European Commission Approves AbbVie s RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2]
- Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RINVOQ met all primary and met key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis[2-6]
- Approvals underscore AbbVie s longstanding commitment to deliver innovative medicines for people living with rheumatic diseases ....

United Kingdom , Clin Rheumatol , Tom Hudson , Iain Mcinnes , European Commission , American College Of Rheumatology , Spondyloarthritis Research Consortium , Assessment Of Spondyloarthritis International Society , Exchange Commission , European Union , Abbvie Deutschland Gmbh Co , Versus Arthritis Professor , Spondyloarthritis International Society , Serious Adverse Events , Marketing Authorization , Psoriatic Arthritis , Ankylosing Spondylitis Disease Activity Scores , Research Consortium , Bath Ankylosing Spondylitis Functional Index , Safety Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Vie Deutschland Gmbh , Accessed January , Patients With Rheumatoid , Upadacitinib Versus Placebo ,

MAXIMISE: Secukinumab significantly improves signs, symptoms of axial disease in PsA

MAXIMISE: Secukinumab significantly improves signs, symptoms of axial disease in PsA
Disclosures:
Baraliakos reports grant or research support from AbbVie, and Novartis; consulting fees from AbbVie, Bristol Myers Squibb, Celgene, Chugai, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB; and speakers fees from AbbVie, Bristol Myers Squibb, Celgene, Chugai, MSD, Novartis, Pfizer, and UCB. Please see the study for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published. ....

Nordrhein Westfalen , Xenofon Baraliakos , University Bochum , Assessment Of Spondyloarthritis International Society , Ruhr University Bochum , Adobe Stock , Axial Manifestations , Psoriatic Arthritis , Visual Analogue Score , Spondyloarthritis International Society , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , மதிப்பீடு ஆஃப் ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் , சொரியாடிக் கீல்வாதம் , காட்சி அனலாக் மதிப்பெண் , ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் ,

Spinal Benefits Seen With Cosentyx in PsA

email article
Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.
The primary endpoint of a 20% response on the criteria of the Assessment of Spondyloarthritis International Society (ASAS20) at week 12 was met by 63% and 66% of patients randomized to subcutaneous secukinumab, 300 mg or 150 mg every 4 weeks, compared with 31% of those given placebo, according to Xenofon Baraliakos, MD, PhD, of Rheumazentrum Ruhrgebiet, Ruhr-University of Bochum in Germany, and colleagues.
Compared with placebo, the odds ratios of achieving ASAS20 responses were 3.8 (95% CI 2.4-6.1) and 4.4 (95% CI 2.7-7,
P ....

Nordrhein Westfalen , Rheumazentrum Ruhrgebiet , Secukinumab Cosentyx , Xenofon Baraliakos , Group For Research , University Of Bochum , Assessment Of Spondyloarthritis International Society , Spondyloarthritis International Society , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , குழு க்கு ஆராய்ச்சி , மதிப்பீடு ஆஃப் ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் , ஸ்பொந்தய்லோஆறத்ரிடிச் சர்வதேச சமூகம் ,